Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment
Clinical trial NCT05460507 · RECRUITING
Trial details
- NCT number
- NCT05460507
- Sponsor
- Plus Therapeutics
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-12-12
- Primary completion
- 2028-03-01
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.